

Russell W Madison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6146432/publications.pdf>

Version: 2024-02-01

87
papers

2,156
citations

393982

19
h-index

243296

44
g-index

87
all docs

87
docs citations

87
times ranked

2757
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	0.8	474
2	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	0.9	228
3	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	13.7	185
4	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1560-1568.	0.5	158
5	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	0.8	118
6	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1312-1323.	0.5	103
7	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	3.2	101
8	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	0.9	75
9	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
10	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	1.6	58
11	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 124-128.	0.9	52
12	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	0.9	41
13	Targetable gene fusions and aberrations in genitourinary oncology. <i>Nature Reviews Urology</i> , 2020, 17, 613-625.	1.9	35
14	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
15	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	3.0	30
16	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1282-1293.	7.7	28
17	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	0.9	27
18	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
20	Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. <i>Journal of Clinical Oncology</i> , 2020, 38, 9511-9511.	0.8	22
21	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
22	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	3.2	20
23	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. <i>European Urology Oncology</i> , 2021, 4, 297-300.	2.6	18
24	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	1.9	16
25	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2022, 81, 37-47.	0.9	16
26	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	1.3	14
27	Clinicopathologic, genomic and protein expression characterization of 356 <i>ROS1</i> fusion driven solid tumors cases. <i>International Journal of Cancer</i> , 2021, 148, 1778-1788.	2.3	14
28	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	1.9	13
29	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	1.7	13
30	Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. <i>JCO Precision Oncology</i> , 2021, 5, 1354-1376.	1.5	12
31	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
32	Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 457-465.	0.9	8
33	Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion. <i>Journal of Thoracic Oncology</i> , 2018, 13, e148-e150.	0.5	7
34	<i>RAS</i> Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	1.9	7
35	Real-world association of <i>HER2/ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , 2021, 17, 4101-4114.	1.1	7
36	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique <i>HER2</i> exon 20 insertions.. Journal of Clinical Oncology, 2019, 37, 9063-9063.	0.8	7
38	Abstract 2231: Utility of plasma tumor fraction (TF) to inform sensitivity of FoundationOne Liquid CDx (F1LCDx). Cancer Research, 2021, 81, 2231-2231.	0.4	6
39	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. Journal of Clinical Oncology, 2019, 37, 4581-4581.	0.8	6
40	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. BMC Cancer, 2017, 17, 197.	1.1	5
41	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	2.0	5
42	Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection.. Journal of Clinical Oncology, 2022, 40, 187-187.	0.8	5
43	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 578-578.	0.8	4
44	Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5527-5527.	0.8	3
45	CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non-small cell lung cancer (aNSCLC).. Journal of Clinical Oncology, 2022, 40, 9045-9045.	0.8	3
46	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. Lung Cancer: Targets and Therapy, 2020, Volume 11, 33-39.	1.3	2
47	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. Journal of Clinical Oncology, 2021, 39, 25-25.	0.8	2
48	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. Journal of Clinical Oncology, 2021, 39, 4045-4045.	0.8	2
49	Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2021, 39, 9101-9101.	0.8	2
50	Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2020, 38, 5017-5017.	0.8	2
51	FGFR2: A pan-genomic target.. Journal of Clinical Oncology, 2019, 37, 3099-3099.	0.8	2
52	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. Blood, 2019, 134, 1437-1437.	0.6	2
53	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. Journal of Clinical Oncology, 2022, 40, 448-448.	0.8	2
54	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	1.5	2

#	ARTICLE	IF	CITATIONS
55	<p>TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 81-86.	1.3	1
56	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	1.5	1
57	Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. Journal of Clinical Oncology, 2021, 39, 485-485.	0.8	1
58	Genomic landscape of <i>MSH6</i>-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	0.8	1
59	Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic <i>BRCA1/2</i> (<i>sBRCA</i>) or other homologous recombination (HR)-pathway gene mutations (mut) treated with PARP inhibitors (PARPi).. Journal of Clinical Oncology, 2021, 39, 10512-10512.	0.8	1
60	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
61	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 4579-4579.	0.8	1
62	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	1
63	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 551-551.	0.8	1
64	<i>FGFR2</i>-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.. Journal of Clinical Oncology, 2019, 37, 72-72.	0.8	1
65	<i>KRAS</i> amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).. Journal of Clinical Oncology, 2019, 37, 70-70.	0.8	1
66	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).. Journal of Clinical Oncology, 2019, 37, 391-391.	0.8	1
67	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. Journal of Clinical Oncology, 2022, 40, 4156-4156.	0.8	1
68	In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.. Journal of Clinical Oncology, 2021, 39, 337-337.	0.8	0
69	Comprehensive genomic profiling (CGP) to reveal new opportunities and challenges in muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2021, 39, 479-479.	0.8	0
70	Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2021, 39, 142-142.	0.8	0
71	Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, e17035-e17035.	0.8	0
72	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5054-5054.	0.8	0
74	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. Journal of Clinical Oncology, 2016, 34, 4573-4573.	0.8	0
75	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. Journal of Clinical Oncology, 2018, 36, 4063-4063.	0.8	0
76	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2018, 36, 12041-12041.	0.8	0
77	Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 416-416.	0.8	0
78	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. Journal of Clinical Oncology, 2019, 37, 460-460.	0.8	0
79	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. Journal of Clinical Oncology, 2019, 37, 4535-4535.	0.8	0
80	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).. Journal of Clinical Oncology, 2019, 37, 4540-4540.	0.8	0
81	Analysis of EGFR mutant urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 4545-4545.	0.8	0
82	KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).. Journal of Clinical Oncology, 2019, 37, e15565-e15565.	0.8	0
83	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 9566-9566.	0.8	0
84	Interim results of PEANUT: pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2020, 38, 494-494.	0.8	0
85	Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).. Journal of Clinical Oncology, 2020, 38, 310-310.	0.8	0
86	Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.. Journal of Clinical Oncology, 2020, 38, 3517-3517.	0.8	0
87	Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.. Journal of Clinical Oncology, 2020, 38, 9591-9591.	0.8	0